VIENNA—Mycobacterial cell wall DNA complex (MCC) may provide an alternative to cystectomy for patients with non-muscle invasive bladder cancer refractory to bacillus Calmette-Guérin (BCG) treatment, according to preliminary study findings.
VIENNA—Testosterone replacement therapy benefits hypogonadal men without adversely affecting prostate safety, according to the largest international trial of hypogonadal men receiving the treatment.
VIENNA—Tadalafil can improve erectile dysfunction (ED) and lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) in men who suffer from both problems, data suggest.
VIENNA—Adjuvant radiotherapy following radical prostatectomy (RP) for locally advanced prostate cancer (PCa) is associated with better outcomes than early salvage radiotherapy, according to a study.
VIENNA—PSA screening for prostate cancer (PCa) decreases the risk of PCa-related metastatic disease, according to study findings presented at the European Association of Urology 26th annual congress.
VIENNA—Lower urinary tract symptoms (LUTS) in men may provide useful information about the risk of having prostate cancer (PCa) diagnosed, data from two studies presented at the 26th Annual Congress of the European Association of Urology.
PHOENIX—Chronic kidney disease (CKD) patients with anemia have significantly lower levels of 25 vitamin D (25D) than those without anemia, researchers concluded.
PHOENIX—Marked hyperglycemia in diabetic patients on chronic peritoneal dialysis (CPD) are at increased risk of death, a study found.
Physician influence emerges as the greatest factor contributing to the decision.
Novartis Pharmaceuticals, based in East Hanover, NJ, has received FDA approval of Zortress (everolimus) oral tablets for preventing rejection of kidney transplants in adult patients at low-to-moderate immunologic risk.
